LLY is trading at $1,094.23 (+3.4%) following Eli Lilly's announcement of a definitive agreement to acquire Orna Therapeutics for up to $2.4 billion.
- The deal marks a strategic expansion into in vivo cell engineering and circular RNA therapeutics, with Orna's lead program targeting B cell-driven autoimmune diseases through a novel CAR-T approach.
- The acquisition positions Lilly at the forefront of next-generation cell therapy innovation by addressing the logistical and clinical limitations of current ex vivo CAR-T treatments.
- Analyst sentiment remains bullish as JPMorgan recently raised its price target to $1,300, citing strong growth potential in the obesity and diabetes markets.